In the news release, Aradigm Announces Fourth Quarter and Year End 2005 Financial Results,” issued earlier today by Aradigm (NASDAQ: ARDM), we are advised by the company that the second bullet under Recent Highlights should read “In September 2005, we announced an intellectual property access agreement with an undisclosed top tier global pharmaceutical company in the area of smoking cessation. This agreement granted the undisclosed company access to Aradigm’s intellectual property specific to the pulmonary delivery of nicotine using its patented AERx® technology.” rather than “In January 2006, we announced a licensing and development deal with an undisclosed top tier global pharmaceutical company in the area of smoking cessation. This agreement granted the undisclosed company access to Aradigm’s intellectual property specific to the pulmonary delivery of nicotine using its patented AERx® technology with the goal of developing a commercial development program.” as originally issued. Complete corrected text follows.
